نتایج جستجو برای: glycemic benefit of sglt2 inhibitors

تعداد نتایج: 21186431  

Journal: :The Journal of pharmacology and experimental therapeutics 2014
Chiaki Kuriyama Jun Zhi Xu Seunghun Paul Lee Jenson Qi Hirotaka Kimata Tetsuhiro Kakimoto Keiko Nakayama Yoshinori Watanabe Nobuhiko Taniuchi Kumiko Hikida Yasuaki Matsushita Kenji Arakawa Akira Saito Kiichiro Ueta Masaharu Shiotani

Sodium-glucose cotransporter 2 (SGLT2) plays a major role in renal glucose reabsorption. To analyze the potential of insulin-independent blood glucose control, the effects of the novel SGLT2 inhibitor canagliflozin on renal glucose reabsorption and the progression of hyperglycemia were analyzed in Zucker diabetic fatty (ZDF) rats. The transporter activity of recombinant human and rat SGLT2 was ...

2017
Atsushi Tanaka Koichi Node

A growing body of evidence suggests that sodium-glucose cotransporter 2 (SGLT2) inhibitors appear to be a powerful option to improve the cardiovascular (CV) prognosis in high CV-risk patients with type 2 diabetes. Despite a significant reduction in major adverse CV events with SGLT2 inhibitor treatment, however, an unexpected increased risk of amputation was observed in the CANVAS program and t...

Journal: :The Australasian medical journal 2014
Robert G Moses Stephen Colagiuri Carol Pollock

The prevalence of type 2 diabetes mellitus (T2DM) is rising in Australia. Sodium glucose co-transporter 2 (SGLT2) inhibitors are an emerging treatment for T2DM. SGLT2 inhibitors offer a novel approach to lowering hyperglycaemia by suppressing renal glucose reabsorption and increasing urinary glucose excretion. The increased urinary glucose excretion has also been associated with caloric loss an...

2017
Yingying Yang Shi Chen Hui Pan Yun Zou Bo Wang Guixia Wang Huijuan Zhu

BACKGROUND We aimed to assess the safety and efficiency of the novel sodium glucose co-transporter 2 (SGLT2) inhibitor in combinations with insulin for type 1 and type 2 diabetes mellitus (T1DM and T2DM). METHODS We searched Medline, Pubmed, Embase, and the Cochrane Collaboration Library from January 2010 to December 2016 without restriction of language. FDA data and Clinical Trials (http://w...

2017
Xiaoling Cai Liwei Ji Yifei Chen Wenjia Yang Lingli Zhou Xueyao Han Simin Zhang Linong Ji

AIMS/INTRODUCTION To evaluate the efficacy of weight changes from baseline of the sodium-glucose cotransporter 2 (SGLT2) inhibitors treatment and glucagon-like peptide-1 (GLP-1) analogs treatment after comparisons with a placebo in type 2 diabetes patients, and the associated factors. MATERIALS AND METHODS Studies were searched from when recording began, June 2004, until June 2015, and re-sea...

2016
Alla K. Ovsyannikova Oksana D. Rymar Elena V. Shakhtshneider Vadim V. Klimontov Elena A. Koroleva Natalya E. Myakina Mikhail I. Voevoda

Maturity-onset diabetes of the young (MODY) is a heterogeneous group of diseases associated with gene mutations leading to dysfunction of pancreatic β-cells. Thirteen identified MODY variants differ from each other by the clinical course and treatment requirement. Currently, MODY subtypes 1-5 are best-studied, descriptions of the other forms are sporadic. This article reports a MODY12 clinical ...

پایان نامه :وزارت علوم، تحقیقات و فناوری - دانشگاه شاهد - دانشکده هنر 1391

now-a-days graphic design plays a major role in influencing culture, society, business, and customers, in such a way that one could look upon every individual as a potential customer. graphic designers seek to identify customers needs and find an intelligent solution for them. correct identification and understanding of those needs is the first step towards achieving ones goals. marketing knowh...

2017
Sanjay Kalra A. G. Unnikrishnan Manash Baruah Pallavi Kawatra Jignesh Ved

Pharmaco-ergonomics implies tailoring the drug therapy to an individual patient's requirement(s). The development of sodium-glucose cotransporter 2 inhibitor (SGLT2-i) agents has impelled multiple clinical considerations, in the management of type-2 diabetes. This paper attempts to summarize the pharmaco-ergonomic considerations for these agents, in the form of an SGLT2-i qualification tool, ba...

Journal: :Endocrinology 2008
H S Freitas G F Anhê K F S Melo M M Okamoto M Oliveira-Souza S Bordin U F Machado

Mutations in Na(+)-glucose transporters (SGLT)-2 and hepatocyte nuclear factor (HNF)-1alpha genes have been related to renal glycosuria and maturity-onset diabetes of the young 3, respectively. However, the expression of these genes have not been investigated in type 1 and type 2 diabetes. Here in kidney of diabetic rats, we tested the hypotheses that SGLT2 mRNA expression is altered; HNF-1alph...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید